scholarly journals Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

Leukemia ◽  
2008 ◽  
Vol 23 (5) ◽  
pp. 983-985 ◽  
Author(s):  
D Bruennert ◽  
A Czibere ◽  
I Bruns ◽  
R Kronenwett ◽  
N Gattermann ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukaemia ◽  
Philadelphia Chromosome ◽  
Myelogenous Leukaemia ◽  
Imatinib Therapy ◽  
Cd34 Cells ◽  
Philadelphia Chromosome Positive

The role of the c- oncogene in Philadelphia chromosome positive chronic myelogenous leukaemia

1987 ◽  
Vol 23 (11) ◽  
pp. 1756
Author(s):  
Gerard C. Grosveld ◽  
Andre B.C. Hermans ◽  
Annelies de Klein ◽  
Dirk Bootsma ◽  
Nora Heisterkamp ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukaemia ◽  
Philadelphia Chromosome ◽  
Myelogenous Leukaemia ◽  
Philadelphia Chromosome Positive

A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia

1990 ◽  
Vol 76 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Francisco Cervantes ◽  
María Rozman ◽  
Jordi Rosell ◽  
Alvaro Urbano-Ispizua ◽  
Emilio Montserrat ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Chronic Myelogenous Leukaemia ◽  
Blast Crisis ◽  
Philadelphia Chromosome ◽  
Myelogenous Leukaemia ◽  
Philadelphia Chromosome Positive

scholarly journals The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Kazuhito Naka ◽  
Ryosuke Ochiai ◽  
Eriko Matsubara ◽  
Chie Kondo ◽  
Kyung-Min Yang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Cell Cycle Progression ◽  
Chronic Myelogenous Leukaemia ◽  
Cancer Recurrence ◽  
Myelogenous Leukaemia ◽  
Cell Nuclei ◽  
Hypomorphic Mutation ◽  
Lysophospholipase D

Abstract Although advanced lipidomics technology facilitates quantitation of intracellular lipid components, little is known about the regulation of lipid metabolism in cancer cells. Here, we show that disruption of the Gdpd3 gene encoding a lysophospholipase D enzyme significantly decreased self-renewal capacity in murine chronic myelogenous leukaemia (CML) stem cells in vivo. Sophisticated lipidomics analyses revealed that Gdpd3 deficiency reduced levels of certain lysophosphatidic acids (LPAs) and lipid mediators in CML cells. Loss of Gdpd3 also activated AKT/mTORC1 signalling and cell cycle progression while suppressing Foxo3a/β-catenin interaction within CML stem cell nuclei. Strikingly, CML stem cells carrying a hypomorphic mutation of Lgr4/Gpr48, which encodes a leucine-rich repeat (LRR)-containing G-protein coupled receptor (GPCR) acting downstream of Gdpd3, displayed inadequate disease-initiating capacity in vivo. Our data showing that lysophospholipid metabolism is required for CML stem cell maintenance in vivo establish a new, biologically significant mechanism of cancer recurrence that is independent of oncogene addiction.

scholarly journals Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

2004 ◽  
Vol 125 (2) ◽  
pp. 187-195 ◽  
Author(s):  
Maha M. T. El-Zimaity ◽  
Hagop Kantarjian ◽  
Moshe Talpaz ◽  
Susan O'Brien ◽  
Francis Giles ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukaemia ◽  
Philadelphia Chromosome ◽  
Myelogenous Leukaemia
Sign in / Sign up

Export Citation Format

Share Document